Long acting somatostatin analogue for the treatment of refractory RA
Table 1 Patients' characteristics at the beginning of the study Patient Age Duration of RA Disease stage* Drugs used before somatostatin[dagger] Drugs used while taking somatostatin Rheumatoid factor 1 60 13 III 1, 2, 6, 7, 9 Indometacin + 2 66 20 III 1, 2, 6, 7, 9 Indometacin + 3 70 25 III 1,...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2002-06, Vol.61 (6), p.573-573 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 573 |
|---|---|
| container_issue | 6 |
| container_start_page | 573 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 61 |
| creator | Koseoglu, F Koseoglu, T |
| description | Table 1 Patients' characteristics at the beginning of the study Patient Age Duration of RA Disease stage* Drugs used before somatostatin[dagger] Drugs used while taking somatostatin Rheumatoid factor 1 60 13 III 1, 2, 6, 7, 9 Indometacin + 2 66 20 III 1, 2, 6, 7, 9 Indometacin + 3 70 25 III 1, 2, 4, 6, 8, 9 Indometacin + 4 60 7 II 1, 3, 6, 9 Piroxicam + 5 63 30 III 1, 2, 6, 9 Indometacin - 6 55 8 II 1, 3, 6, 7, 9 Indometacin + 7 60 15 III 1, 4, 6, 7, 9 Indometacin + 8 42 8 II 1, 2, 6, 9 Piroxicam + 9 55 7 II 1, 2, 6, 8, 9 Indometacin + 10 57 14 III 1, 2, 3, 6, 9 Indometacin + 11 55 6 II 1, 5, 6, 9 Indometacin + *Classified using the criteria of Steinbrocker, et al. [dagger]Drugs: 1, non-steroidal anti-inflammatory drug; 2, hydroxychoroquine; 3, gold; 4, penicillamine; 5, methotrexate; 6, corticosteroids; 7, cyclosporin; 8, interferon α; 9, sulfasalazine. Koseoglu and Koseoglu conducted a shorter study of only eight weeks as compared with our 14 week study, where we saw continued improvement after eight weeks. [...]accepted American College of Rheumatology criteria for the evaluation of response to treatment in patients with RA were not used, making it difficult to compare the results. |
| doi_str_mv | 10.1136/ard.61.6.573 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A87011635</galeid><sourcerecordid>A87011635</sourcerecordid><originalsourceid>FETCH-LOGICAL-b553t-e77c7a4f303f2395adf1321cdb4ae715b9eb81125acec33f734d14fa888b533</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotvCjTOKhASXZvHEsZ29IC1boJUWEAUBN8txxmmWJC62g9p_j1e7agFVyIeRPZ_fs-cR8gToHICJl9o3cwFzMeeS3SMzKEWVF1TQ-2RGKWV5uRDygByGsElbWkH1kBxAQalgpZiRk7Ub20yb2KUS3KCjC1GnXaZH3bt2wsw6n8ULzKJHHQccY-Zs5tH6dMv56-x8-Yg8sLoP-Hhfj8jnt2--rE7z9cd3Z6vlOq85ZzFHKY3UpWWU2YItuG4ssAJMU5caJfB6gXUFUHBt0DBmJSsbKK2uqqrmjB2RVzvVy6kesDHpJV736tJ3g_bXyulO_d0ZuwvVul8KJC8BRBJ4vhfw7ueEIaqhCwb7Xo_opqAkCCkkLxL47B9w4yaf5hGSlpRVySnjiTreUa3uUXWjdcnVtDhiMncj2i4dLytJt95bPL8DT6vBoTN38Xt5410Iad43PwWqtsmrlLwSoIRKySf86Z_TuYX3Ud_6dyHi1U1f-x9KSCa5-vB1pc7Fp9fi-7f3iib-xY6vh83_rX8DIz3FOw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777845035</pqid></control><display><type>article</type><title>Long acting somatostatin analogue for the treatment of refractory RA</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Koseoglu, F ; Koseoglu, T</creator><creatorcontrib>Koseoglu, F ; Koseoglu, T</creatorcontrib><description>Table 1 Patients' characteristics at the beginning of the study Patient Age Duration of RA Disease stage* Drugs used before somatostatin[dagger] Drugs used while taking somatostatin Rheumatoid factor 1 60 13 III 1, 2, 6, 7, 9 Indometacin + 2 66 20 III 1, 2, 6, 7, 9 Indometacin + 3 70 25 III 1, 2, 4, 6, 8, 9 Indometacin + 4 60 7 II 1, 3, 6, 9 Piroxicam + 5 63 30 III 1, 2, 6, 9 Indometacin - 6 55 8 II 1, 3, 6, 7, 9 Indometacin + 7 60 15 III 1, 4, 6, 7, 9 Indometacin + 8 42 8 II 1, 2, 6, 9 Piroxicam + 9 55 7 II 1, 2, 6, 8, 9 Indometacin + 10 57 14 III 1, 2, 3, 6, 9 Indometacin + 11 55 6 II 1, 5, 6, 9 Indometacin + *Classified using the criteria of Steinbrocker, et al. [dagger]Drugs: 1, non-steroidal anti-inflammatory drug; 2, hydroxychoroquine; 3, gold; 4, penicillamine; 5, methotrexate; 6, corticosteroids; 7, cyclosporin; 8, interferon α; 9, sulfasalazine. Koseoglu and Koseoglu conducted a shorter study of only eight weeks as compared with our 14 week study, where we saw continued improvement after eight weeks. [...]accepted American College of Rheumatology criteria for the evaluation of response to treatment in patients with RA were not used, making it difficult to compare the results.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.61.6.573</identifier><identifier>PMID: 12006346</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Aged ; Antirheumatic Agents - administration & dosage ; Arthritis, Rheumatoid - drug therapy ; Drug dosages ; Evaluation ; Humans ; Injections, Subcutaneous ; Laboratories ; Matters Arising ; Middle Aged ; Octreotide - administration & dosage ; Patients ; Pilot Projects ; Recurrence ; Rheumatoid arthritis ; Somatostatin</subject><ispartof>Annals of the rheumatic diseases, 2002-06, Vol.61 (6), p.573-573</ispartof><rights>Copyright 2002 by Annals of the Rheumatic Diseases</rights><rights>COPYRIGHT 2002 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2002 Copyright 2002 by Annals of the Rheumatic Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b553t-e77c7a4f303f2395adf1321cdb4ae715b9eb81125acec33f734d14fa888b533</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754116/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754116/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27928,27929,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12006346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koseoglu, F</creatorcontrib><creatorcontrib>Koseoglu, T</creatorcontrib><title>Long acting somatostatin analogue for the treatment of refractory RA</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Table 1 Patients' characteristics at the beginning of the study Patient Age Duration of RA Disease stage* Drugs used before somatostatin[dagger] Drugs used while taking somatostatin Rheumatoid factor 1 60 13 III 1, 2, 6, 7, 9 Indometacin + 2 66 20 III 1, 2, 6, 7, 9 Indometacin + 3 70 25 III 1, 2, 4, 6, 8, 9 Indometacin + 4 60 7 II 1, 3, 6, 9 Piroxicam + 5 63 30 III 1, 2, 6, 9 Indometacin - 6 55 8 II 1, 3, 6, 7, 9 Indometacin + 7 60 15 III 1, 4, 6, 7, 9 Indometacin + 8 42 8 II 1, 2, 6, 9 Piroxicam + 9 55 7 II 1, 2, 6, 8, 9 Indometacin + 10 57 14 III 1, 2, 3, 6, 9 Indometacin + 11 55 6 II 1, 5, 6, 9 Indometacin + *Classified using the criteria of Steinbrocker, et al. [dagger]Drugs: 1, non-steroidal anti-inflammatory drug; 2, hydroxychoroquine; 3, gold; 4, penicillamine; 5, methotrexate; 6, corticosteroids; 7, cyclosporin; 8, interferon α; 9, sulfasalazine. Koseoglu and Koseoglu conducted a shorter study of only eight weeks as compared with our 14 week study, where we saw continued improvement after eight weeks. [...]accepted American College of Rheumatology criteria for the evaluation of response to treatment in patients with RA were not used, making it difficult to compare the results.</description><subject>Aged</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Drug dosages</subject><subject>Evaluation</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Laboratories</subject><subject>Matters Arising</subject><subject>Middle Aged</subject><subject>Octreotide - administration & dosage</subject><subject>Patients</subject><subject>Pilot Projects</subject><subject>Recurrence</subject><subject>Rheumatoid arthritis</subject><subject>Somatostatin</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kUFv1DAQhS0EotvCjTOKhASXZvHEsZ29IC1boJUWEAUBN8txxmmWJC62g9p_j1e7agFVyIeRPZ_fs-cR8gToHICJl9o3cwFzMeeS3SMzKEWVF1TQ-2RGKWV5uRDygByGsElbWkH1kBxAQalgpZiRk7Ub20yb2KUS3KCjC1GnXaZH3bt2wsw6n8ULzKJHHQccY-Zs5tH6dMv56-x8-Yg8sLoP-Hhfj8jnt2--rE7z9cd3Z6vlOq85ZzFHKY3UpWWU2YItuG4ssAJMU5caJfB6gXUFUHBt0DBmJSsbKK2uqqrmjB2RVzvVy6kesDHpJV736tJ3g_bXyulO_d0ZuwvVul8KJC8BRBJ4vhfw7ueEIaqhCwb7Xo_opqAkCCkkLxL47B9w4yaf5hGSlpRVySnjiTreUa3uUXWjdcnVtDhiMncj2i4dLytJt95bPL8DT6vBoTN38Xt5410Iad43PwWqtsmrlLwSoIRKySf86Z_TuYX3Ud_6dyHi1U1f-x9KSCa5-vB1pc7Fp9fi-7f3iib-xY6vh83_rX8DIz3FOw</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>Koseoglu, F</creator><creator>Koseoglu, T</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20020601</creationdate><title>Long acting somatostatin analogue for the treatment of refractory RA</title><author>Koseoglu, F ; Koseoglu, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b553t-e77c7a4f303f2395adf1321cdb4ae715b9eb81125acec33f734d14fa888b533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Drug dosages</topic><topic>Evaluation</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Laboratories</topic><topic>Matters Arising</topic><topic>Middle Aged</topic><topic>Octreotide - administration & dosage</topic><topic>Patients</topic><topic>Pilot Projects</topic><topic>Recurrence</topic><topic>Rheumatoid arthritis</topic><topic>Somatostatin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koseoglu, F</creatorcontrib><creatorcontrib>Koseoglu, T</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>Proquest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koseoglu, F</au><au>Koseoglu, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long acting somatostatin analogue for the treatment of refractory RA</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>61</volume><issue>6</issue><spage>573</spage><epage>573</epage><pages>573-573</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Table 1 Patients' characteristics at the beginning of the study Patient Age Duration of RA Disease stage* Drugs used before somatostatin[dagger] Drugs used while taking somatostatin Rheumatoid factor 1 60 13 III 1, 2, 6, 7, 9 Indometacin + 2 66 20 III 1, 2, 6, 7, 9 Indometacin + 3 70 25 III 1, 2, 4, 6, 8, 9 Indometacin + 4 60 7 II 1, 3, 6, 9 Piroxicam + 5 63 30 III 1, 2, 6, 9 Indometacin - 6 55 8 II 1, 3, 6, 7, 9 Indometacin + 7 60 15 III 1, 4, 6, 7, 9 Indometacin + 8 42 8 II 1, 2, 6, 9 Piroxicam + 9 55 7 II 1, 2, 6, 8, 9 Indometacin + 10 57 14 III 1, 2, 3, 6, 9 Indometacin + 11 55 6 II 1, 5, 6, 9 Indometacin + *Classified using the criteria of Steinbrocker, et al. [dagger]Drugs: 1, non-steroidal anti-inflammatory drug; 2, hydroxychoroquine; 3, gold; 4, penicillamine; 5, methotrexate; 6, corticosteroids; 7, cyclosporin; 8, interferon α; 9, sulfasalazine. Koseoglu and Koseoglu conducted a shorter study of only eight weeks as compared with our 14 week study, where we saw continued improvement after eight weeks. [...]accepted American College of Rheumatology criteria for the evaluation of response to treatment in patients with RA were not used, making it difficult to compare the results.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>12006346</pmid><doi>10.1136/ard.61.6.573</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2002-06, Vol.61 (6), p.573-573 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754116 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Aged Antirheumatic Agents - administration & dosage Arthritis, Rheumatoid - drug therapy Drug dosages Evaluation Humans Injections, Subcutaneous Laboratories Matters Arising Middle Aged Octreotide - administration & dosage Patients Pilot Projects Recurrence Rheumatoid arthritis Somatostatin |
| title | Long acting somatostatin analogue for the treatment of refractory RA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T04%3A25%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20acting%20somatostatin%20analogue%20for%20the%20treatment%20of%20refractory%20RA&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Koseoglu,%20F&rft.date=2002-06-01&rft.volume=61&rft.issue=6&rft.spage=573&rft.epage=573&rft.pages=573-573&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.61.6.573&rft_dat=%3Cgale_pubme%3EA87011635%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777845035&rft_id=info:pmid/12006346&rft_galeid=A87011635&rfr_iscdi=true |